New Treatment for HER2+ Survivors
For certain women with metastatic HER2+ breast cancer, life just got a little bit brighter – literally. On January 29, the FDA granted approval to a new combination drug therapy – Tykerb (lapatinib), and Femara (letrozole) – for post-menopausal women with estrogen-receptive, HER2-positive (HER2+) metastatic breast... Read more








